Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Stewart

Showing results (1011-1020 of 1,171) with videos related to

Pageof 118
Sort By:
Cancer|April 2, 2021
Association of race and health care system with disease stage and survival in veterans with larynx cancerRohith S Voora, Nikhil V Kotha, Abhishek Kumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecanClinton F Stewart, John C Panetta, Melinda A O'Shaughnessy, et al.
Cancer Chemotherapy and Pharmacology|May 13, 1999
Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumorsW C Zamboni, L C Bowman, M Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018Katherine E Warren, Stewart Goldman, Ian F Pollack, et al.
Cancer Research|October 20, 2004
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in miceClinton F Stewart, Markos Leggas, John D Schuetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2013
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium studyAmar Gajjar, Clinton F Stewart, David W Ellison, et al.
Cancer Chemotherapy and Pharmacology|March 1, 2015
Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further studyYogesh T Patel, Megan O Jacus, Nidal Boulos, et al.
Cancer Medicine|April 1, 2024
Characterization and impact of non-canonical WNT signaling on outcomes of urothelial carcinomaMargaret Meagher, Harris Krause, Andrew Elliott, et al.
Pediatric Blood & Cancer|April 22, 2011
Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumorsLisa M McGregor, Clinton F Stewart, Kristine R Crews, et al.
Scientific Reports|September 1, 2023
Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcomaJin-Ah Kim, Kenneth A Crawford, Piero A Spada, et al.
Pageof 118

Showing results (1011-1020 of 1,171) with videos related to

Sort By:
Pageof 118
Cancer|April 2, 2021
Association of race and health care system with disease stage and survival in veterans with larynx cancerRohith S Voora, Nikhil V Kotha, Abhishek Kumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecanClinton F Stewart, John C Panetta, Melinda A O'Shaughnessy, et al.
Cancer Chemotherapy and Pharmacology|May 13, 1999
Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumorsW C Zamboni, L C Bowman, M Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018Katherine E Warren, Stewart Goldman, Ian F Pollack, et al.
Cancer Research|October 20, 2004
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in miceClinton F Stewart, Markos Leggas, John D Schuetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2013
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium studyAmar Gajjar, Clinton F Stewart, David W Ellison, et al.
Cancer Chemotherapy and Pharmacology|March 1, 2015
Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further studyYogesh T Patel, Megan O Jacus, Nidal Boulos, et al.
Cancer Medicine|April 1, 2024
Characterization and impact of non-canonical WNT signaling on outcomes of urothelial carcinomaMargaret Meagher, Harris Krause, Andrew Elliott, et al.
Pediatric Blood & Cancer|April 22, 2011
Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumorsLisa M McGregor, Clinton F Stewart, Kristine R Crews, et al.
Scientific Reports|September 1, 2023
Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcomaJin-Ah Kim, Kenneth A Crawford, Piero A Spada, et al.
Pageof 118